| No. |
DrugBank |
Drug (Description in trials)
[Number of descriptions] |
KEGG DRUG * | KEGG GENES *
[Number of genes] |
KEGG PATHWAY
[Number of pathways] |
Disease ID *
[Number of diseases] |
| 1 | Bevacizumab | [4] Bevacizumab; Bevacizumab (avastin) and imatinib mesylate (gleevec); Bevacizumab (genitical recombination); Submucosal bevacizumab; | D06409 |
[1] VEGFA |
[21] AGE-RAGE signaling pathway in diabetic complications, Bladder cancer, EGFR tyrosine kinase inhibitor resistance, Fluid shear stress and atherosclerosis, Focal adhesion, HIF-1 signaling pathway, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, MAPK signaling pathway, MicroRNAs in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Relaxin signaling pathway, Renal cell carcinoma, Rheumatoid arthritis, VEGF signaling pathway |
[9] 13, 34, 85, 86, 87, 89, 227, 280, 331 |
| 2 | Chloride ion | - | - |
- |
- |
[17] 6, 11, 13, 14, 34, 46, 51, 96, 97, 127, 168, 193, 227, 228, 288, 297, 299 |
| 3 | Doxycycline | [7] Antimicrobial therapy: co-trimoxazole or doxycycline; Doxycycline; Doxycycline 100 mg capsules; Doxycycline hyclate; Doxycycline hyclate ph.eur; Interferon beta 1a, oral doxycycline; Treatment with systemic therapy (doxycycline); | D00307
D02129
D03903
D03904
D07876 |
- |
- |
[15] 13, 23, 28, 46, 84, 85, 89, 96, 97, 158, 162, 167, 227, 280, 299 |
| 4 | Estriol | [2] Estriol; Vaginal estriol; | D00185
D01986 |
[2] ESR1, ESR2 |
[9] Breast cancer, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Pathways in cancer, Prolactin signaling pathway, Proteoglycans in cancer, Thyroid hormone signaling pathway |
[2] 13, 227 |
| 5 | Etamsylate | [1] Etamsylate; | D01282 |
- |
- |
[1] 227 |
| 6 | Interferon alfa-2b | [1] Interferon alfa-2b; | D02745 |
[2] IFNAR1, IFNAR2 |
[17] Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway |
[3] 25, 34, 227 |
| 7 | Itraconazole | [2] Itraconazole; Itraconazole/voriconazole; | D00350 |
- |
- |
[4] 3, 65, 227, 299 |
| 8 | Mupirocin | [2] Mupirocin; Mupirocin intranasal creme; | D01076
D02195 |
- |
- |
[2] 227, 299 |
| 9 | Octreotide | [5] Gallium-68-dota-n-octreotide; Octreotide; Octreotide lar; Octreotide lar / sandostatin lar (lar=long acting release); Octreotide-lar; | D00442
D06495 |
[1] SSTR2 |
[4] Gastric acid secretion, Growth hormone synthesis, secretion and action, Neuroactive ligand-receptor interaction, cAMP signaling pathway |
[8] 67, 75, 84, 85, 89, 96, 193, 227 |
| 10 | Pazopanib | [1] Pazopanib; | D05380 |
- |
- |
[1] 227 |
| 11 | Pomalidomide | [4] Pomalidomide; Pomalidomide (cc-4047; Pomalidomide and dexamethasone; Pomalidomide oral product; | D08976 |
[2] IL6, TNF |
[76] AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Cellular senescence, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Cytosolic DNA-sensing pathway, Dilated cardiomyopathy (DCM), EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, FoxO signaling pathway, Graft-versus-host disease, HIF-1 signaling pathway, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, Measles, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Pertussis, Prion diseases, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Transcriptional misregulation in cancer, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
[6] 28, 34, 51, 85, 227, 331 |
| 12 | Propranolol | [5] Atenolol or propranolol; Losartan and atenolol or propranolol; Propranolol; Propranolol hcl cf 40 mg tablet; Propranolol treatment; | D00483
D08443 |
[3] ADRB1, ADRB2, ADRB3 |
[11] Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Dilated cardiomyopathy (DCM), Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Thermogenesis, cAMP signaling pathway, cGMP-PKG signaling pathway |
[5] 6, 158, 167, 227, 278 |
| 13 | Ranibizumab | [3] Intravitreal injection ranibizumab; Ranibizumab; Ranibizumab injection (0.5 mg); | D05697 |
[1] VEGFA |
[21] AGE-RAGE signaling pathway in diabetic complications, Bladder cancer, EGFR tyrosine kinase inhibitor resistance, Fluid shear stress and atherosclerosis, Focal adhesion, HIF-1 signaling pathway, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, MAPK signaling pathway, MicroRNAs in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Relaxin signaling pathway, Renal cell carcinoma, Rheumatoid arthritis, VEGF signaling pathway |
[4] 34, 166, 227, 301 |
| 14 | Sodium chloride | [14] 0.9% sodium chloride; 0.9% sodium chloride (normal saline); 0.9% sodium chloride injection; 0.9% w/v sodium chloride solution; Isotonic sodium chloride solution; Physiological serum (sodium chloride); Sodium chloride; Sodium chloride (7%); Sodium chloride 0,9%; Sodium chloride 6%; Sodium chloride solution; Sodium chloride solution 0.9%; Sodium chloride solvent; Sodium pyruvate in 0.9% sodium chloride solution; | D02056 |
- |
- |
[19] 6, 11, 13, 14, 17, 34, 46, 51, 53, 67, 78, 86, 97, 168, 193, 227, 228, 288, 299 |
| 15 | Tamoxifen | [3] Tamoxifen; Tamoxifen 40 mg daily for one year; Tamoxifen citrate; | D00966
D08559 |
[2] ESR1, ESR2 |
[9] Breast cancer, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Pathways in cancer, Prolactin signaling pathway, Proteoglycans in cancer, Thyroid hormone signaling pathway |
[4] 2, 86, 113, 227 |
| 16 | Thalidomide | [9] Fpf 300 (thalidomide); Melphalan, thalidomide and dexamethasone; Thalidomide; Thalidomide (drug); Thalidomide 100mg; Thalidomide 150mg; Thalidomide celgene - 50 mg capsula rigida - uso orale - blister (pvc/pe/aclar/alu) 28 capsule; Thalidomide pharmion; Thalidomide, cyclophosphamide and prednisone; | D00754 |
[1] TNF |
[61] AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
[18] 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 |
| 17 | Timolol | [4] Timolol; Timolol gel; Timolol nasal spray; Topical timolol maleate; | D00378
D00603
D08600 |
[2] ADRB1, ADRB2 |
[10] Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Dilated cardiomyopathy (DCM), Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway |
[2] 157, 227 |
| 18 | Tranexamic acid | [2] Tranexamic acid; Tranexamic acid 100 mg/ml; | D01136 |
[1] PLG |
[4] Complement and coagulation cascades, Influenza A, Neuroactive ligand-receptor interaction, Staphylococcus aureus infection |
[5] 46, 70, 215, 227, 288 |